| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Outline of Final Research Achievements |
Rats were separated into the untreated (UT) group or the RIC-treated group. RIC treatment was performed by 5 cycles of 5 min of bilateral hindlimb ischemia and 5 min of reperfusion once a day for 4 weeks. MI size, LVEF was improved in the RIC group v.s the UT group. The LVEF in the RIC was improved. RIC treatment also prevented the deterioration of LV diastolic function. MI-induced LV interstitial fibrosis in the boundary region and oxidant stress were significantly attenuated by RIC. MicroRNA-29a (miR-29a) was highly expressed in the exosomes and the marginal area of the RIC. Insulin-like growth factor 1 receptor was highly expressed both in the exosomes and remote non-infarcted myocardiumof the RIC group.
Ten patients with HF, RIC treatment was performed twice a day for 1 week. 4 cycles of 5 minutes inflation and 5 minutes deflation of a blood pressure cuff to create intermittent arm ischemia. RIC treatment increased CFR from 1.9±0.4 to 2.3±0.7 in patients with HF (P<0.03).
|
